Bcl-xL antisense oligonucleotides radiosensitise colon cancer cells

V Wacheck¹, E Seizer², P Günsberg¹, T Lucas¹, H Meyer¹, C Thallinger¹, BP Monia³ and B Jansen*,¹,4

¹Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria; ²Department of Radiotherapy and Radiobiology, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria; ³Isis Pharmaceuticals Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, USA; ⁴The Prostate Centre, University of British Columbia, 2733 Heather Street, Vancouver, BC, Canada V5Z 3J5

Advanced colorectal cancer is a malignancy with poor response to various treatment modalities including ionising radiation (IR) and chemotherapy. Both IR and chemotherapeutic agents have been shown to act by inducing apoptosis, a type of cell death antagonised by the Bcl-xL gene product. Since approximately 60% of human colon cancers express Bcl-xL, it was the aim of this study to explore the potential of Bcl-xL antisense oligonucleotides as a novel radiosensitisation strategy. Caco-2 colon cancer cells were treated with Bcl-xL antisense oligonucleotides in combination with IR or cisplatin, and Bcl-xL protein expression, apoptosis, cell viability and clonogenic survival were examined. Bcl-xL antisense oligonucleotide specifically reduced the Bcl-xL protein level by almost 50% in Caco-2 cells. The decreased threshold for the induction of apoptosis resulted in a 300% increase of apoptosis after IR or cisplatin treatment and led to a 60% reduction of cell proliferation beyond response rates achieved with IR. These data suggest that Bcl-xL is an important factor contributing to the treatment resistance of human colon cancer. Specific reduction of Bcl-xL protein levels by antisense oligonucleotides qualifies as a promising therapeutic strategy for colon cancer that may help overcome resistance and improve clinical outcome in this malignancy.

British Journal of Cancer (2003) 89, 1352–1357. doi:10.1038/sj.bjc.6601254 www.bjcancer.com

© 2003 Cancer Research UK

Keywords: antisense oligonucleotides; Bcl-xL; radiosensitisation; colon cancer

Colorectal carcinoma is the second leading cause of cancer death in Western countries with an incidence rate of 1:3000 (Midgley and Kerr, 1999; Greenlee et al., 2000). Surgical resection is the first choice of therapy for localised tumours, but at least 40% of patients with colorectal cancer will develop local recurrence or metastases during the course of the disease. For patients with advanced colorectal cancer, adjuvant chemotherapy and/or ionising radiation (IR) offer a small but significant survival advantage (Midgley and Kerr, 1999; Wils et al., 2001). While in the US postoperative (chemo)radiotherapy is considered the adjuvant treatment of choice, most European investigators have advocated for preoperative intensive short-course irradiation instead (Wils et al., 2001). Nevertheless, irrespective of the therapeutic strategy selected, advanced colorectal cancer remains a prime example for poor response to adjuvant treatment due to low sensitivity to both IR and chemotherapy.

The mechanisms responsible for the resistance of this malignancy to IR or chemotherapeutic drugs are not yet fully understood. Apoptosis is currently a subject of intense research, and there is growing evidence that tumour cells, at least in part, die by apoptosis in response to IR or cytotoxic treatments (Deozei, 1994; Huang et al., 1997; Coultas and Strasser, 2000; Evan and Vousden, 2001; Reed, 2001). The members of the Bcl-2 multigene family are a pivotal set of apoptotic regulators that consist of partially interacting proteins highly conserved from nematodes to mammals (Kroemer, 1997; Antonsson and Martinou, 2000; Tsujimoto and Shimizu, 2000). Among the various Bcl-like proteins, the effects and functions of Bcl-x in controlling apoptosis induced by IR or chemotherapy have been studied recently. The Bcl-x gene is a Bcl-2 homologue and plays an important role in the regulation of programmed cell death in a variety of tissues (Xerri et al., 1998; Tsujimoto and Shimizu, 2000). Bcl-x is alternatively spliced into two mRNAs. The protein product of the larger Bcl-x mRNA (Bcl-xL) functions as a repressor of programmed cell death (Kroemer, 1997), whereas the smaller splicing product Bcl-xS encodes a protein capable of accelerating cell death (Antonsson and Martinou, 2000; Tsujimoto and Shimizu, 2000). While it becomes increasingly clear that the two close relatives Bcl-2 and Bcl-xL show different cellular expression patterns and may complement each other’s antiapoptotic function, the exact mechanisms of action remain unclear (Kroemer and Reed, 2000; Robertson and Orrenius, 2000).

The antiapoptotic effects of Bcl-xL against IR- and chemotherapy-induced apoptosis have been demonstrated in various human cancer cell lines (Huang et al., 1997; Amarante-Mendes et al., 1998; Nagane et al., 1998; Srinivasan et al., 1998). The most pronounced effects were observed in cells containing the highest levels of Bcl-xL expression.

Antisense (AS) oligonucleotides are modified single-strand stretches of nucleic acids capable of inhibiting protein expression by complexing with the complementary target mRNA preventing translation. Antisense oligonucleotides hold great promise as agents for specific manipulation of gene expression and have been used to inhibit gene expression both in vitro and in vivo (Kitada

*Correspondence: Dr B Jansen, Department of Clinical Pharmacology, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria; E-mail: Burkhard.Jansen@univie.ac.at
Revised 13 June 2003; accepted 8 July 2003
et al., 1994; Keith et al., 1995). Bcl-xL downregulation by AS oligonucleotides has been observed in different types of cancer cells leading to an increase in susceptibility to apoptotic stimuli (Amarante-Mendes et al., 1998; Lebedeva et al., 2000). Recently, it was shown that Bcl-xL AS oligonucleotides are capable of sensitising colon cancer cells in vitro to 5-fluorouracil (Nita et al., 2000). Furthermore, bcl-2/bcl-xL bispecific oligonucleotides significantly reduced Bcl-xL expression that leads to increased apoptosis and delayed tumour growth in a xenotransplantation model for colon cancer (Gautschi et al., 2001). Taylor et al. (1999) demonstrated specific downregulation of Bcl-xL by AS oligonucleotides (ISIS 16009) in keratinocytes and epithelial cells and sensitisation to UV-B radiation- and cisplatin-induced apoptosis. However, the effect of Bcl-xL AS oligonucleotides on radiosensitivity of colon cancer has not yet been explored.

Given the overexpression of Bcl-xL protein in more than 60% of human colon cancers (Krajewska et al., 1996; Maurer et al., 1998) and its positive correlation with poor prognosis (Biroccio et al., 2001), we hypothesised that downregulation by Bcl-xL by AS oligonucleotides may sensitise colon cancer cells to IR or cisplatin.

MATERIALS AND METHODS

Cell culture

The human colorectal carcinoma cell line Caco-2 was obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in basal tissue culture medium (DMEM) supplemented with 8% foetal calf serum, 1% penicillin, and 1% streptomycin (all Gibco BRL, Paisley, UK) in a humidified 5% CO2, 95% ambient air atmosphere at 37°C. For treatment, Caco-2 cells were incubated with oligonucleotides and exposed to IR or cisplatin at the time points and concentrations as indicated. Cells were irradiated with a conventional radiation source (Stapilipan, Siemens, Munich, Germany) at a dose rate of 1 Gy/min⁻¹. Cisplatin was obtained from Ebewe (Unterach, Austria).

Immune blotting

Western blotting of lysed oligonucleotide-treated cells was performed using chemiluminescence detection (Tropix, Bedford, MA, USA). Antibodies reacting with Bcl-xL and actin were obtained from BD PharMingen (Franklin Lakes, NJ, USA) and Sigma (St Louis, MO, USA), respectively. Equal protein loading in each lane was documented by actin protein expression. The expression levels of proteins were determined by densitometric analysis of autoradiograms with a Herolab E.A.S.Y. RH densitometer (Herolab, Wiesloch, Germany) and the E.A.S.Y. Win32 software (Herolab). Signal strength of each Bcl-xL signal was normalised to actin and the ratios between Bcl-xL protein expression in AS oligonucleotides-treated cell extracts and control extracts were calculated. Changes of protein expression below 20% were not regarded as significant.

Oligonucleotides

HPLC purified 20-mer 2'-O-methoxymethyl chimerical phosphorothioate oligonucleotides complementary to the human Bcl-xL were provided by ISIS Pharmaceuticals (Carlsbad, CA, USA). The sequence of the Bcl-xL AS oligonucleotide ISIS 16009 was 5'-CTA CGC TTT CCA CGC ACA GT-3'. An 8-base mismatch (MM) oligonucleotide (ISIS 16967) 5'-CTC CAA TGT CCG CTC AAG GT-3' was used as an internal control oligonucleotide. Underlined bases indicate 2'-O-methoxymethyl modification. For the screening experiments, further Bcl-xL antisense oligonucleotides were tested: ISIS 15999 (5'-TCC CGG TTG CTC TGA GAC AT-3'), ISIS 16011 (5'-CTG GAT CCA AGG CTG CTC TAG GT-3'), and ISIS 22783 (5'-CTG GAT CCA AGG CTC TAG GT-3'). All oligonucleotides were resuspended in 0.9% saline solution.

Delivery of oligonucleotides

Cells were seeded at a density of 0.25 × 10⁶ ml⁻¹ in six-well plates 24 h before oligonucleotide treatment. Cultures were then incubated for 4 h at 37°C with 200 nm oligonucleotide in the presence of 10 µg ml⁻¹ lipofectin (Gibco) as an uptake enhancer, according to the manufacturer’s protocol. After incubation, the oligonucleotide–lipofectin mixture was replaced by complete medium and cells were cultivated as described above. For the screening experiments, cells were incubated for 48 or 72 h with oligonucleotides at a concentration of 50 µM without uptake-enhancing lipofectin.

Assessment of cell viability and clonogenic survival

For the assessment of cell growth in vitro, cells were incubated with oligonucleotides and exposed to IR at the time points and doses as indicated. Cisplatin was used at a dose almost doubling the number of apoptotic cells compared to untreated cells (50 µM). At 24, 48, 72, and 96 h after oligonucleotide treatment, the number of viable cells was determined by a tetrazolium salt-based assay (WST-1 assay, Roche Diagnostics, Basel, Switzerland).

For determination of clonogenic survival following IR, cells were seeded in six-well plates and exposed to increasing single doses of IR. Postirradiation cells were plated in 6 cm dishes at a seeding density of approx. 1000 cells per well (in triplicate). After an incubation period of 10 days, culture dishes were stained with crystal violet and colonies of >50 cells were counted at low magnification.

Flow cytometry

Apoptotic cells were identified by their sub-diploid DNA content using flow cytometrical analysis as previously described (Nicoletti et al., 1991). Cells were washed in PBS, fixed in ice-cold 70% ethanol for a minimum of 1 h, washed in PBS and incubated in PBS containing 0.1% DNA-free RNase A and 100 µg ml⁻¹ propidium iodide for 30 min and 1.5 × 10⁶ events analysed on a FACScalibur flow cytometer (Becton Dickinson, NJ, USA) with an argon laser tuned at 488 nm. Gates were set to exclude subcellular particles. The percent gated populations represent cells that are hypochromatic due to chromatin condensation and contain subdiploid DNA contents (percentage of apoptotic cells). The apoptotic morphology of this cell population was confirmed by fluorescence microscopy.

Statistical analysis

Statistical significance between treatment groups was determined using one-way ANOVA and Bonferroni post hoc test analysis. P-values of <0.05 were considered to be of statistical significance.

RESULTS

Specific downregulation of Bcl-xL in Caco-2 cells

In a screening experiment to identify the most potent Bcl-xL AS oligonucleotides, Caco-2 cells were incubated with four different AS oligonucleotides targeting different sites of the Bcl-xL mRNA as described in the Material and Methods section. After a 48-h incubation period at a concentration of 50 µM, the Bcl-xL AS oligonucleotides ISIS 16009 targeting the translation initiation codon site of Bcl-xL resulted in the most prominent downregulation of Bcl-xL protein expression by approximately one-third compared to the saline control (Figure 1A). Although a longer
incubation period of 72 h revealed marked downregulation of Bcl-x protein by all the AS oligonucleotides applied, ISIS 16009 was still the most potent AS oligonucleotide (Figure 1B).

We therefore focused further experiments on ISIS 16009 as the lead compound. Using an uptake-enhancing lipid (lipofectin), oligonucleotide concentrations were reduced to nanomolar concentrations minimising possible nonspecific oligonucleotide effects reported earlier at micromolar concentrations (Stein, 1995). Treatment of Caco-2 cells with 200 nM ISIS 16009 for 4 h in the presence of lipofectin led to a significant reduction of Bcl-x protein expression after 48 h by almost 50% compared to saline control (Figure 2; 47% AS/Sal, s.d. ±5%). No significant change of Bcl-x protein expression in cells incubated in the presence of the same concentration of MM oligonucleotide were observed (110% MM/Sal, s.d. ±9%; P > 0.13). Concomitantly performed Western blot analysis of the cellular lysates demonstrated no changes in Bcl-xS expression levels after oligonucleotide treatment (Figure 2; 96% AS/Sal, s.d. ±3%; 86% MM/Sal, s.d. ±4%; both P > 0.1). Prolongation of the incubation period to 72 h led to no more pronounced downregulation of Bcl-xL protein expression (data not shown).

### Bcl-xL AS oligonucleotides lower the apoptotic threshold

To study the influence of Bcl-xL AS oligonucleotides on facilitating apoptosis in Caco-2 cells, the relative percentage of apoptotic cells compared to untreated controls was assessed by flow cytometry. Cells with a sub-G0/G1 DNA content due to chromatin condensation were considered apoptotic (Nicoletti et al., 1991). Caco-2 cancer cells were incubated for 4 h with saline (Sal), antisense (AS), or eight-base mismatch (MM) oligonucleotides at a dose of 200 nM in the presence of uptake-enhancing lipofectin. After 10 h of incubation period, Caco-2 cells were treated with IR. Increasing doses of IR (0–12 Gy) resulted in a dose-dependent rise in the number of apoptotic cells up to a doubling of apoptotic cells at a dose of 12 Gy compared to nonirradiated cells. Treatment of Caco-2 colon cells with ISIS 16009 Bcl-xL AS oligonucleotides alone significantly enhanced the rate of apoptotic cells compared to saline controls (Figure 3; P < 0.05), whereas no significant increase of apoptotic cell death in the group treated with MM oligonucleotides was observed. However, the combination of Bcl-xL AS oligonucleotides and IR resulted in a pronounced increase of apoptotic cell death by about 300% compared to irradiated Caco-2 cells pretreated with either saline or MM oligonucleotides at all IR doses examined (Figure 3). These differences were highly statistically significant (P < 0.001). The combination of ISIS 16009 Bcl-xL AS oligonucleotide and an IR dose of 12 Gy approximately doubled the rate of apoptotic cells compared to AS oligonucleotide treatment alone (P < 0.012). No statistically significant differences were observed between the

#### Figure 1
Screening of Bcl-xL AS oligonucleotides: Western blots of Caco-2 cells 48 h (A) and 72 h (B) after treatment with four different AS oligonucleotides at a concentration of 50 μM; lane 1: saline (Sal), lane 2: ISIS 22783, lane 3: ISIS 16009, lane 4: ISIS 16011, lane 5: ISIS 15999, and lane 6: saline (Sal).

#### Figure 2
Bcl-xL downregulation by Bcl-xL AS oligonucleotides (ISIS 16009): Western blot of Caco-2 cells 48 h after a 4-h treatment with 200 nM oligonucleotides in the presence of 10 μg ml⁻¹ lipofectin; lane 1: saline (Sal), lane 2: ISIS 16009 Bcl-xL AS oligonucleotides (AS), lane 3: 8-base mismatch oligonucleotides (MM). A representative blot of four independent experiments is presented.

#### Figure 3
Bcl-xL AS oligonucleotides facilitate the induction of apoptosis in human colon cancer cells. Caco-2 cancer cells were incubated for 4 h with saline (Sal), antisense (AS), or eight-base mismatch (MM) oligonucleotides at a concentration of 200 nM in the presence of 10 μg ml⁻¹ lipofectin. After 48 h, cells were treated with increasing doses of IR (0–12 Gy). At 96 h after oligonucleotide treatment, cells were harvested and analysed by FACS for apoptosis. Columns represent mean percentages of apoptotic cell death from four independent experiments; bars= s.d.
saline control and MM oligonucleotide pretreated cells supporting a specific Bcl-xL AS oligonucleotide mode of action.

Additionally, we investigated the combination of Bcl-xL AS oligonucleotides and the chemotherapeutic agent cisplatin. Cisplatin at a dose of 50 μM in combination with ISIS 16009 AS oligonucleotides almost doubled the rate of apoptotic cells compared to saline or MM oligonucleotides pretreated cells (Sal ± Cis 7.2%, s.d. ± 2.7%; AS + Cis 18.9%, s.d. ± 5.9%; MM + Cis 5.1%, s.d. ± 1.7%; both P < 0.002; data not shown). Levels of apoptosis after cisplatin exposure in cultures pretreated with MM oligonucleotides did not differ significantly from the ones in the saline group.

Bcl-xL AS oligonucleotides radiosensitise Caco-2 cells

To determine the influence of Bcl-xL AS oligonucleotides on cell viability and treatment resistance, Caco-2 colorectal cancer cells were treated with ISIS 16009 Bcl-xL AS, MM oligonucleotides or saline in combination with IR at the same time points and concentrations as described above.

We first determined cell viability after AS oligonucleotide monotherapy in a time course experiment by the tetrazolium-based WST-1 assay (Figure 4A). Bcl-xL AS oligonucleotides alone significantly reduced the viability of Caco-2 cells compared to MM control or sham-treated cells beginning 72 h after incubation with oligonucleotides (Figure 4A; P < 0.003). At 96 h, cell viability was reduced by one-third relative to the MM control (66% AS vs MM, s.d. ± 13%; P < 0.001). Cell viability of the MM oligonucleotide-treated cells did not differ from the saline control except at 96 h after oligonucleotide administration when a moderate inhibition of cell growth compared to saline treatment was observed (P < 0.05).

For combination experiments, Caco-2 cells were exposed to IR 48 h after incubation with oligonucleotides. Starting from 72 h after AS oligonucleotide treatment, combinations of Bcl-xL AS oligonucleotides and IR significantly reduced the viability of Caco-2 cells compared to controls (Figure 4B; all at least < 0.005). In dose–response experiments, ISIS 16009 significantly sensitised human Caco-2 colon cancer cells to increasing IR doses of 2, 6 and 12 Gy by 30–60% relative to irradiated control cells (Figure 4C; P < 0.05). MM oligonucleotide treatment combined with IR did not lead to results statistically significantly different from those obtained with irradiated saline groups at any dose or time point investigated.

It is known that induction of apoptosis as well as tetrazolium-based short-term proliferation assays do not necessarily predict overall sensitivity of cancer cells to genotoxic treatment (Brown and Wouters, 1999). Especially for studies assessing the fraction of cells maintaining their reproductive integrity after IR, it is sensible to perform colony-forming assays. We therefore performed clonogenic assays of Caco-2 cells treated with Bcl-xL AS oligonucleotides at increasing doses of IR (Figure 5). Administration of ISIS 16009 alone resulted in a statistical nonsignificant trend towards reduced clonogenic survival compared to the MM control. However, the combination of Bcl-xL AS oligonucleotides and IR at doses of 2 and 6 Gy significantly reduced colony formation in a dose-dependent manner by at least two-thirds compared to MM or saline pretreated cells (Figure 5; P < 0.05). Again, MM oligonucleotide treatment combined with both IR doses did not differ statistically significantly from corresponding saline groups. At the highest radiation dose of 12 Gy, we observed no reliable colony formation in any treatment group.

We furthermore examined the chemosensitising effect obtained by the combination of Bcl-xL AS oligonucleotides and cisplatin. Caco-2 cells treated with ISIS 16009 and cisplatin (50 μM) revealed more than a 75% reduction in cell viability after 96 h compared to cisplatin-treated controls (78% AS + Cis vs Sal + Cis, s.d. ± 5%; 77% AS + Cis vs MM + Cis, s.d. ± 5%; both P < 0.001; data not shown). Similar, clonogenic survival of Bcl-xL AS oligonucleotide and cisplatin treated Caco-2 cells was significantly reduced by about 70% compared to the respective MM and saline controls (P < 0.001; data not shown).

DISCUSSION

Failure of cells to undergo apoptosis or programmed cell death may contribute to the treatment resistance of colon cancer (Kim et al., 1999). Decreasing the apoptotic threshold, mediated at least in part by the antiapoptotic Bcl-2 family member Bcl-xL, should lead to higher response rates of apoptosis-inducing treatment modalities (Maurer et al., 1998). In this study, we demonstrated a sensitisation of colorectal cancer cells to IR by specific down-regulation of the long splicing variant of Bcl-xL protein with Bcl-xL AS
AS oligonucleotides. This regulation lowered the apoptotic threshold and resulted in a pronounced inhibition of cell viability and clonogenic survival with a significant increase in IR-mediated apoptosis. In accordance with previous reports, the clonogenic survival assay was more sensitive than the tetrazolium-based proliferation assay, especially at higher radiation doses (Banasiak et al, 1999). This may be explained by the differences in the end points of both assays. The WST-1 tetrazolium assay (used for the time course experiments) scores the number of metabolically active cells, whereas the clonogenic assay is dependent on colony formation and therefore relies on cells that maintain their reproductive integrity (Banasiak et al, 1999). Thus, cells that have lost their reproductive potential immediately following treatment with ASO/irradiation or after a few cell divisions but which are still viable will still be scored by the WST-1 test, but not be recorded in the clonogenic assay.

High levels of antiapoptotic Bcl-2 family members are frequently found in tumours. Bcl-xL and Bcl-2 both have the potential to block the process of apoptosis induced by the same stimuli (Huang et al, 1997). However, they may play nonredundant and distinct biological roles in cell survival and drug resistance depending on the type of tissue. There is growing evidence that among the antiapoptotic members of the Bcl-2 family, Bcl-xL rather than Bcl-2 is a crucial factor responsible for the regulation of apoptotic cell death in colon cancer (Maurer et al, 1998). In more than 60% of all colon cancer, Bcl-xL staining is more pronounced than in normal colon epithelium, whereas Bcl-2 expression was reported to be too low for detection by Northern blotting (Krajewska et al, 1996; Maurer et al, 1998). There is a significant correlation between the chemosensitivity of this malignancy and the Bcl-xL to Bax ratio, which is not observed to the same extent in the Bcl-2 to Bax ratio (Nita et al, 1998).

A screening approach using micromolar concentrations of four different Bcl-xL AS oligonucleotides led us to select ISIS 16009 as the AS oligonucleotide reducing Bcl-xL expression most potently. Using lipofectin as a cationic uptake enhancer allowed us to reduce ISIS 16009 AS oligonucleotides concentrations to the nanomolar range that minimises nonantisense oligonucleotide effects reported to occur at micromolar concentrations (Stein, 1995). Notably, ISIS 16009 Bcl-xL AS oligonucleotides did not reduce the alternative, short splicing proapoptotic variant of the Bcl-x gene nor did they shift the splicing pattern of Bcl-x pre-mRNA from Bcl-xL to Bcl-xS (Mercatante et al, 2002). This finding further supports a specific antisense mechanism of action for the Bcl-xL AS oligonucleotide used in this study.

Cellular susceptibility to apoptosis is thought to be determined by the ratio of pro- and antiapoptotic Bcl-2 family members rather than the total amounts present in a given cell (Tsujimoto and Shimizu, 2000). In this study, downregulation of the Bcl-xL protein product by about 50% compared to MM- or saline control-sensitised Caco-2 colorectal cancer cells to IR or cisplatin. Since it was not necessary to block completely Bcl-xL expression to observe the effects demonstrated, our findings support the hypothesis of a critical balance between pro- and antiapoptotic factors in the tightly regulated process of apoptosis. This is of special interest since it is known that proapoptotic Bax mRNA is overexpressed in 75% of colorectal cancer specimen (Maurer et al, 1998). In the relative absence of its heterodimer partner Bcl-xL due to AS oligonucleotide treatment, Bax should preferentially form homodimers resulting in facilitated programmed cell death upon apoptotic stimulation.

The development of antisense technology represents a promising strategy to improve conventional therapy outcomes. For colon cancer, several apoptosis-related targets for AS oligonucleotide approaches have already been tested. Treatment with EGFR AS oligonucleotides showed an inhibition of human colon cancer cell growth with potentiation of inhibitory cell growth effects in combination with cytotoxic drugs (Ciardiello et al, 2001). p21 AS oligonucleotides sensitised colon cancer cells in vitro by down-regulation of IR induced p21 expression and increased apoptotic cell death (Tian et al, 2000). Bispecific AS oligonucleotides targeting Bcl-xL and Bcl-2 have been shown to reduce colon cancer cell growth in vitro and in vivo (Gautschi et al, 2001). Combination strategies with chemotherapy, a concept even more attractive in theory, have not been addressed in this study.

Bcl-xL AS oligonucleotides in combination with the cytostatic agent 5-fluorouracil have been reported recently to increase apoptosis and reduce cell growth by 40% in colon cancer cells (Nita et al, 2000). In our study, using a different Bcl-xL AS oligonucleotide sequence in a different colon cancer cell line, the chemosensitisation approach was successfully extended to a more than 70% reduction of cell viability in combination with the cytotoxic chemotherapeutic agent cisplatin. Single-agent Bcl-xL AS oligonucleotide treatment had similar effects on cell death as those reported in the study mentioned above. However, considering possible therapeutic applications, systemic administration of myelosuppressive chemotherapy in combination with Bcl-xL AS oligonucleotides may lead to harmful side effects. Among the antiapoptotic Bcl-2 family members, Bcl-xL rather than Bcl-2 is presumed to be a key player in the survival of haematopoietic cell lineages, developing megakaryocytes and for the lifespan of mature platelets (Sanz et al, 2001). Even though clinical data for Bcl-xL AS oligonucleotides are not yet available, it will be prudent to monitor closely the patients treated with combinations of myelosuppressive chemotherapeutics such as 5-fluorouracil or cisplatin for haematological side effects. As an indirect line of support for this concern, thrombocytopenia as dose-limiting toxicity as well as transient leukopenia have been observed in the first clinical trial combining a mild myelosuppressive standard chemotherapeutic regimen with Bcl-2 AS oligonucleotides in melanoma (Jansen et al, 2000).

It appears reasonable to speculate that combining the systemic administration of Bcl-xL AS oligonucleotides with a localised treatment approach such as IR restricted to the tumour site could circumvent or at least minimise anticipated dose-limiting haematological side effects without negative impact on its sensitisation effect on tumor cells.

In this study, we report that Bcl-xL AS oligonucleotides are capable of sensitising colon cancer cells to IR, one of the most commonly used treatment strategies for localised colorectal cancer.
in an adjuvant setting. Cell viability and clonogenic survival in Bcl-xL AS oligonucleotides pretreated colon cancer cells was blocked by about 60% compared to irradiated control cells. These findings underline the role of Bcl-xL protein as a resistance factor in colon cancer and as an attractive target for therapeutic concepts capable of specifically modulating protein expression such as in AS oligonucleotides strategies. Certainly, these promising first data deserve further evaluation and need to be confirmed in preclinical animal models. However, given the feasibility of AS oligonucleotide administration reported from first clinical trials (Jansen and Zangemeister-Wittke, 2002), the results reported here may provide the basis for the use of Bcl-xL AS oligonucleotides as a rational radiosensitising strategy to help improve treatment outcome in colon cancer patients.

ACKNOWLEDGEMENTS

The work in BJ Laboratory was supported by the ‘Austrian National Bank’, the ‘Austrian Science Fund’, the ‘Kommission Önkologie’, the ‘Hygiene Fonds’, the ‘Virologie Fonds’, the ‘Niarchos Foundation’ and the ‘Kamillo Eisner Stiftung’.

REFERENCES

Amarante-Mendes GP, McGahan AJ, Nishioka WK, Afar DE, Witte ON, Green DR (1998) Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with upregulation of Bcl-xL. Oncogene 16: 1383 – 1390

Antonsson B, Martinou JC (2000) The Bcl-2 protein family. Exp Cell Res 256: 50 – 57

Banasiak D, Barnetson AR, Odell RA, Mameghan H, Russell PJ (1999) Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. Radiat Oncol Invest 7: 77 – 85

Biracco A, Benassi B, D’Angnolo I, D’Angelo C, Bugliosi S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG, Calabretta B, Zupi G (2001) c-Myc and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol 158: 1289 – 1299

Brown JM, Wouters BG (1999) Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391 – 1399

Ciaraldi F, Caputo B, Troiani T, Borriello G, Kandimmalla ER, Agrawal S, Mendelssohn J, Bianco AR, Tortora G (2001) Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 93: 172 – 178

Coulitas L, Strasser A (2000) The molecular control of DNA damage-induced cell death. Apoptosis 5: 491 – 507

Desoize B (1994) Anticancer drug resistance and inhibition of apoptosis. Anticancer Res 14: 2291 – 2294

Evans GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342 – 348

Gautschi O, Tschopp S, Olie RA, Leech SH, Simoes-Wust AP, Ziegler A, & 2003 Cancer Research UK

Green DR (1998) Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis. Nature 395: 513 – 519

Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6: 513 – 519

Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95: 5724 – 5729

Nicotelli I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271 – 279

Nita ME, Nagawa H, Tominaga O, Tsuno N, Fuji S, Sasaki S, Fu CG, Takenoue T, Tsuruo T, Muto T (1998) 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 78: 986 – 992

Okerlund DR, Mohler JL, Kole R (2002) Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antisenseoligomers. J Biol Chem 277: 49374 – 49382

Taylor JK, Zhang QQ, Monia BP, Marcusson EG, Dean NM (1999) Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 96: 9734 – 9739

Stein CA (1995) Does antisense exist? Nat Med 1: 519 – 524

Stenbeck K, Johansson T, Abrahamsson M, Persson G, Olofsson C, Bengtsson M (1999) Antiapoptotic protein Bcl-x(L) is up-regulated during megakaryocytic differentiation of CD34(+) progenitors but is absent from senescent megakaryocytes. Exp Hematol 27: 678 – 685

J Immunol Methods 139: 271 – 279

Robertson JD, Orrenius S (2000) Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit Rev Toxicol 30: 609 – 627

Sanz C, Benet I, Richard G, Badia B, Andreu EJ, Frooper F, Fernandez-Luna JL (2001) Antiapoptotic protein Bcl-x(L) is up-regulated during megakaryocytic differentiation of CD34(+) progenitors but is absent from senescent megakaryocytes. Exp Hematol 29: 728 – 735

Tian H, Wittmack EK, Jorgensen TJ (2000) p21WAF1/CIP1 antisense therapy radiosensitises human colon cancer cells by converting growth arrest to apoptosis. Cancer Res 60: 679 – 684

Wils J, O’Dwyer P, Labianca R (2001) Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol 12: 13 – 22

Xerri L, Hassoun J, Devillard J, Birnbaum D, Birg F (1998) BCL-X and the apoptotic machinery of lymphoma cells. Leukemia 12: 451 – 458